We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Electronic Device May Help Diagnose Early Bladder Cancer

By LabMedica International staff writers
Posted on 09 Aug 2019
It is estimated that bladder cancer will affect 80,470 people in the USA this year, and about 17,670 deaths are likely to result from these cases. More...
Doctors diagnose approximately half of all bladder cancers while the cancer is still in situ, while in about one-third the disease has already spread to other parts of the bladder.

Currently, the most common ways of detecting bladder cancer are cystoscopies and urine cytology tests. The former are costly, invasive, and heavily reliant on how the operator performs them, while the latter are not very effective at detecting cancer in its early stages. Additionally, cytology tests are prone to error, as they are not the best tool for telling the difference between inflammation and malignancy.

Bioengineers at the Polytechnic University of València (València, Spain) and their colleagues have developed a complex electronic device as a possible new, efficient, simple, and cost-effective way of detecting bladder cancer in its early stages and monitoring people living with bladder cancer. The devices are called electronic tongues, which are a voltammetric device that can "mimic" the mechanism of human taste by using pattern-information software and sensors that can detect soluble compounds.

The scientists built on previous studies that revealed metabolic differences in the urine of people who had bladder cancer. These previous studies used established metabolomic techniques, such as liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy, to look at the metabolic profiles both before and after surgery. Bladder cancer has a high relapse rate, which is why monitoring patients is particularly important. In 2012, bladder cancer "was the ninth most common malignancy worldwide, with 430,000 newly diagnosed cases.

M. Carmen Martínez Bisbal, PhD, a biochemist and co-author of the study, said, “The preliminary results of this study, with a 75% accuracy rate, indicate that the shapes of current waveforms induced in urine through pulse voltammetry could allow, with an appropriate processing of the data, for a noninvasive diagnosis in the monitoring of patients with bladder cancer.” The study was presented at the XIII International Workshop on Sensors and Molecular Recognition held July 4-5, 2019, in Valencia, Spain.

Related Links:
Polytechnic University of València


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PlGF Test
Quidel Triage PlGF Test
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.